

Attorney Docket No.: 4409.214-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Serial No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, C.

Confirmation No: 2082

For: Peptide Derivatives

RECEIVED  
TTCN CENTER 1600/2900  
02 JAN 29 PM 1:42

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Response to Notice to Comply with Sequence Rules
2. Sequence Listing
3. Copy of Notice to Comply with Sequence Rules
4. Disk Containing Sequence Listing
- 5.

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence  
Commissioner for Patents  
Washington, DC 20231

on October 26, 2001.

Sylvia Gonzalez  
(name of person mailing paper)

  
(signature of person mailing paper)

RECEIVED  
TECH CENTER 1600/2900

02 JAN 29 PM 1:41



Via DHL

Ms. Chin-Min Kam  
USPTO  
Crystal Mall 1  
Arlington, VA 22202

January 28, 2002

Re: Patent Application 09/772,607  
Filed January 30, 2001  
Group Art Unit: 1653  
Confirmation No: 2082  
Polypeptide Derivatives  
Our Reference No: 4409.214-US

Dear Ms. Kam:

Per your phone call to Richard Bork on January 28, 2002, enclosed please a copy of our response filed on October 26, 2001, regarding response for Sequence Listing. We have also enclosed a 3.5" floppy disk containing the Sequence Listing for the above-mentioned reference.

Please do not hesitate to contact me if you require additional material or information.

Best Regards,

Sylvia Gonzalez  
Patent Assistant  
For Richard Bork  
Encls.

Novo Nordisk of North  
America, Inc.

405 Lexington Ave,  
Suite 6400  
New York, NY  
10017-6401

Telephone:  
212-867-0123  
Direct dial:  
212-878-9680  
Telefax:  
212-878-9655

E-mail:  
SGon@novonordisk.com  
Internet:  
www.novodordisk.com

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
  - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
  - Email: [PATIN21HELP@uspto.gov](mailto:PATIN21HELP@uspto.gov)
  - To purchase PatentIn software: (703) 306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

Attorney Docket No. 4409.214-US  
Patent Application entitled: "Peptide Derivatives"  
Applicants: Jonassen et al.  
USSN: 09/772,607

The USPTO hereby acknowledges receipt of the following:

1. Certificate of Mailing
2. Response to Notice to Comply with Sequence Rules
3. Copy of Notice to Comply With Requirements
4. Sequence Listing
5. Disk Containing Sequence Listing

RBoR/SGon  
October 26, 2001

VIA First Class Mail